Robert L. Coleman, MD, FACOG, FACS Second-line maintenance therapy with niraparib (Zejula) improved overall survival (OS) vs active surveillance (AS) in patients with recurrent BRCA wild-type ovarian cancer, according to data from a real-world study presented at the 2023 ASCO Annual Meeting.1 “Overall, the study provided informative data on niraparib’s overall survival in BRCA wild … [Read more…]
ASCO Annual Meeting: © SciePro – stock.adobe.com The addition of the soluble LAG-3 protein eftilagimod alpha (efti; IMP321) to pembrolizumab (Keytruda) produced responses and was well tolerated in patients with metastatic head and neck squamous cell carcinoma (HNSCC), according to data from part C of the phase 2 TACTI-002 trial (NCT03625323) presented at the 2023 … [Read more…]
Virginia G. Kaklamani, MD Findings from a subgroup analysis of the phase 3 EMERALD trial (NCT03778931) presented during the 2023 ASCO Annual Meeting demonstrated elacestrant (Orserdu) elicited prolonged progression-free survival (PFS) compared with standard-of-care (SOC) therapy for patients with estrogen receptor (ER)–positive HER2-negative non-detected ESR1 mutated breast cancer who experienced disease progression within 6 months … [Read more…]